Raytone Biotech Doses First Patient in Clinical Trial for Dry Eye Therapy RTP-008

Raytone Biotech Doses First Patient in Clinical Trial for Dry Eye Therapy RTP-008

By, Admin 5 August 2025

Raytone Biotech, a clinical-stage biotechnology company, has successfully dosed the first patient in its clinical trial of RTP-008, a bioabsorbable tacrolimus lacrimal canaliculus plug, during Q2 2025.

The milestone was achieved at Beijing Tongren Hospital, Capital Medical University, one of China’s leading ophthalmic research centers.

Trial Details

  • Conducted by:
    - Prof. Ying Jie, Director of the Ophthalmology Center
    - Prof. Lei Tian, Deputy Director of the Ophthalmology Center
  • Patient condition: Moderate-to-severe dry eye disease (DED)
  • Initial results:
    - No significant adverse reactions
    - Good tolerability after administration

Understanding the Challenge: Unmet Needs in Dry Eye Disease (DED)

Dry eye disease is multifactorial, affecting the tear film, ocular surface, and neurosensory components. It is characterized by:

  • Tear film instability
  • Hyperosmolarity
  • Chronic ocular inflammation
  • Neurosensory dysfunction

The Vicious Cycle of DED

To manage DED effectively, clinicians must:

  • Identify the root cause: Aqueous tear deficiency, evaporative loss, or both
  • Select tailored interventions based on individual profiles

Why Current Therapies Fall Short

Managing DED, especially in moderate-to-severe cases, remains complex:

  • Physical treatments: e.g., punctal occlusion
  • Pharmacological treatments: e.g., artificial tears, anti-inflammatory eye drops
  • Combination therapy: Often requires
    - 2–3 topical agents
    - Multiple daily doses

This leads to:

  • Poor patient compliance
  • Interrupted treatment cycles
  • Risk of relapse, continuing the vicious cycle

RTP-008: A Game-Changer in DED Treatment

Raytone’s RTP-008 aims to break this cycle by combining physical tear retention and sustained anti-inflammatory action.

Dual Mechanism of Action

  1. Physical Tear Retention
    - Hydrogel plug swells after insertion into the lacrimal canaliculus
    - Reduces tear drainage
    - Prolongs natural tear film retention
  2. Sustained Anti-Inflammatory Delivery
    - Tacrolimus is slowly released over weeks to months
    - Suppresses chronic inflammation
    - Enhanced drug residence time due to the plug’s design

Early Clinical Insights

Principal Investigators’ Statement:
Prof. Ying Jie and Prof. Lei Tian shared:

“RTP-008 showed promising efficacy and safety in preclinical studies. The positive outcome in the first patient is encouraging, and we will monitor closely for further results.”

CEO Commentary and Future Outlook

Dr. Yanbo Ling, CEO of Raytone Biotech, commented:

“This first patient dosing marks our transition from preclinical to clinical phase. We are committed to offering long-lasting, compliance-friendly treatments for dry eye disease. Our pipeline also includes drug-device combination products for both human and veterinary applications.”

About Raytone Biotech

  • Founded: 2021
  • Focus: Ocular bioabsorbable sustained-release therapies
  • Core Technology: iSus® platform
    - Enables precise drug release from days to months
    - Targets limitations of conventional eye drops (frequent dosing, low bioavailability)

Key Product: RTP-008

  • Combines punctal occlusion with sustained tacrolimus delivery
  • Designed for moderate-to-severe DED
  • Aims to improve compliance and enhance long-term efficacy

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!